July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Patrick Hwu: Can We Improve Immunotherapy for Hard-To-Treat Pediatric Cancers Like Rhabdomyosarcoma?
Jul 20, 2025, 09:09

Patrick Hwu: Can We Improve Immunotherapy for Hard-To-Treat Pediatric Cancers Like Rhabdomyosarcoma?

Patrick Hwu, President and CEO of the Moffitt Cancer Center, shared a post on X about recent paper by Lisa Marie Reindl et al., published in Journal of ImmunoTherapy of Cancer.

“Can we improve immunotherapy for hard-to-treat pediatric cancers like rhabdomyosarcoma?

A new study in the Journal for ImmunoTherapy of Cancer explored combining EGFR-targeted CAR natural killer (NK) cells with radiotherapy to treat rhabdomyosarcoma, the most common soft tissue sarcoma in children.

Researchers in the Ullrich Lab and Goethe University engineered primary human NK cells with an EGFR-specific CAR and found they could effectively kill rhabdomyosarcoma cells — including chemotherapy-resistant and patient-derived cells — in preclinical models. The real breakthrough?

Radiotherapy enhanced NK cell tumor infiltration and further reduced tumor growth when combined with CAR NK cell therapy.

This combination approach may offer a promising new strategy for treating aggressive, EGFR-expressing solid tumors.”

Tilte: Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy

Authors: Lisa Marie Reindl, Lida Jalili, Tobias Bexte, Sabine Harenkamp, Sophia Thul, Stephanie Hehlgans, Alina Wallenwein, Florian Rothweiler, Jindrich Cinatl, Martin Michaelis, Halvard Bonig, Elise Gradhand, Meike Vogler, Franz Rödel, Winfried S Wels, Evelyn Ullrich

Read The Full Article at Journal of ImmunoTherapy of Cancer.

Patrick Hwu: Can We Improve Immunotherapy for Hard-To-Treat Pediatric Cancers Like Rhabdomyosarcoma?

More posts featuring Patrick Hwu on OncoDaily.